Skip to main content

Virological Suppression Sustained With Very Early ART in Neonates With HIV-1

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 12, 2023.

By Elana Gotkine HealthDay Reporter

TUESDAY, Dec. 12, 2023 -- For neonates with in utero HIV-1, very early antiretroviral therapy (ART) can achieve sustained virological suppression, according to a study published online Dec. 4 in The Lancet HIV.

Deborah Persaud, M.D., from Johns Hopkins University School of Medicine in Baltimore, and colleagues enrolled infants at 30 research clinics in 11 countries into two cohorts to examine whether very early ART in neonates would restrict HIV-1 reservoirs. Infants at least 34 weeks of gestational age at high risk for in utero HIV-1 with either untreated maternal HIV-1 (cohort 1; 440 infants) or receiving preemptive triple antiretroviral prophylaxis outside of the study (cohort 2; 20 infants) were included. Of these infants, 34 from cohort 1 and 20 from cohort 2 had confirmed in utero HIV-1 and initiated three-drug nevirapine-based ART (cohort 1) and three-drug nevirapine-based prophylaxis then three-drug nevirapine-based ART following HIV diagnosis by age 10 days (cohort 2).

The researchers found that the estimated probability of maintaining undetectable plasma RNA through two years was 33 and 57 percent in cohorts 1 and 2, respectively. No detected HIV-1 DNA was seen among 64 and 71 percent of the 11 and seven infants in cohorts 1 and 2, respectively, who maintained protocol-defined virological control criteria through to study week 108. At week 108, 83 percent of 12 infants in cohort 1 and 100 percent of seven infants in cohort 2 tested HIV-1 antibody-negative.

"Neonatal ART following in-utero HIV-1 transmission is feasible and can reduce reservoir size," the authors write.

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

USPSTF Recommends Screening for Domestic Violence in Pregnant, Postpartum Women

TUESDAY, Oct. 29, 2024 -- The U.S. Preventive Services Task Force recommends screening for intimate partner violence (IPV) in pregnant and postpartum women and women of...

Genome Sequencing Feasible for Newborn Screening

TUESDAY, Oct. 29, 2024 -- Genome sequencing of newborns is both feasible and acceptable for parents of a diverse newborn population, according to a study published online Oct. 24...

Coffee Intake During Pregnancy Not Linked to Neurodevelopmental Issues

FRIDAY, Oct. 25, 2024 -- Maternal coffee consumption during pregnancy does not likely cause neurodevelopmental difficulties (NDs) in offspring, according to a study published...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.